

دراسة التأثير التثبيطي للامبيسيلين على نمو الخلايا السرطانية HCT116

اسراء نجم عبدالله العبادي
مدرس
كلية الطب البيطري
جامعة القادسية

ضفاف جاسم محمد الشكاكي
مدرس مساعد
كلية التربية قسم علوم الحياة
جامعة القادسية

الخلاصة

الامبيسيلين هو مضاد حيوي واسع الطيف يستعمل لعلاج الاخماج المتسببة عن البكتريا الموجبة والسالبة لصبغة كرام. صممت هذه الدراسة لمعرفة تأثير الامبيسيلين على سرطان القولون، كنموذج للسرطان الهضمي، بوجود أو غياب سموم LPS المستخلصة من بكتريا الاشريكية القولونية. اثبتت النتائج وجود تثبيط ملحوظ لنمو الخلايا السرطانية HTC115 مع ان السم البكتيري وحده أمكنه تثبيط نمو الخلايا . ممكن ان نستنتج من هذه الدراسة ان استعمال الامبيسيلين يثبط تقدم نمو هذه الخلايا واستعماله موضعيا مع عمليات استئصال أورام الأمعاء الغليظة يساعد في كبح تقدم الورم. نوصي بإجراء المزيد من الدراسات على المستوى الجزيئي لتقصي الآلية الدقيقة وراء هذا التثبيط.

The growth inhibition effect of Ampicillin against HCT116 cell line

ThifafJasim Mohammad Alshekake

Israa N.A. Al-Ibadi

Email: Najem_Israa@yahoo.com

Abstract

Ampicillin is a common antibiotic used treat infections derived by gram negative and positive bacteria. The hypothesis of this work is to uncover the therapeutic action of Ampicillin in case of human colorectal carcinoma as a model of gastic malignancy in the presence or absence of bacterial toxin. The results indicated that HCT116 viability was significantly attenuated by relatively high doses of Amp in presence or absence of LPS. However LPS treatment alone of high impact on HCT116 cells growth. We conclude that Ampicillin may have therapeutic effect on colorectal cancer upon and lower intestine bacterial infection. Further studies required revealing Ampicillin effect on normal intestinal cells and underneath molecular mechanisms.

Introduction:

Ampicillin, whose chemical formula $C_{16}H_{19}N_3O_4S$ and 3D structure given in Fig.1 (NCBI, 2016), is a wide spectrum antibiotic used either topically, intravenous or intramuscular injection.

Around 50 years ago (Nash and Hugh, 1967) concluded the importance of locally administration of Ampicillin in site of large intestine operation incision before closure to prevent post sequels such as contamination and sepsis Amp. Later in other clinical trials it have been used successfully in during colon surgical operations to prevent infection (Gui et al., 1990) and (Menzel et al., 1996), however another researchers found that previous intake of systemic antibiotic can work the same as a prophylaxis(Raahave et al., 1989) Amp. also used with surgery of gastric cancer removal(Ise et al., 2004)

Between various types of cancer, colon or colorectal cancer which is the cancer of lower part of intestine, is the widest spread gastric cancer in adults. Characterized by up regulation of specific biomarkers mainly Fukutin FKTN (Oo et al., 2016), TM9SF3 (Oo et al., 2014) and (ZDHC14, BST2, DRAM2, DSC2) as demonstrated by Anami et al., (2010). Same researcher identified tetraspanin 8 (TSPAN8), that encodes above-mentioned proteins and promote this type of cancer (Anami et al., 2016). Alongside with Cancer biomarkers, metabolic parameters are employed to predict the development of the colon cancer (Ferroni et al., 2016) also colonoscopy or screening (Telford et al., 2016)

Materials and methods

HCT116 cancer cells obtained from ATCC and maintained in RPMI medium supplemented with the following (10% Fetal calf serum, 1% L-Glutamine, 1% Penicillin-streptomycin) and cells maintained on density $1-2 \times 10^6$ cell per ml. Ampicillin was from sigma catalog number A1593.

Proliferation rate of the cells was determined by using Cell Titer 96® Non-Radioactive Cell Proliferation Assay (MTT) Catalog no G4000.

Cells were normally cultured and counted, later 5000 cells are seeded per well in, 5000 cells per 100 μ l were loaded per each well of F-shape 96 well plate and incubated for 24h, then certain doses are added in 100 μ l for each well except the control were only added media to the cells. Lipopolysaccharides from *Escherichia coli* 055:B5, purchased from Sigma catalog number L6529-1MG

Plates are incubated in 37°C and 5% CO₂, humidified incubator for 96 hours. At the end of incubation time 50 μ l of MTT dye (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) added to the wells and incubated for 3 hours

inside the incubator. Following formation of Formazan crystals at the bottom of the wells, gently aspirated the fluid and 200 μ l of DMSO solvent added to the well and mixed thoroughly. The absorbance of the plate was read on spectrophotometer at 540-690 nm.

Similarity ensemble approach (SEA) are employed for Ampicillin molecular interactions, compound SMILES and name are used in the search tool to investigate the affected biological receptors to Keiser et al., (2007)

Objectives: The aim of this study was to investigate whether Ampicillin treatment can effect on cells activity rather than preventing infection.

Results

Overall, high and low concentrations of Ampicillin reduced the growth of the cells with or without presence of LPS.

LPS treatment alone inhibited 60% of the growth, Extremely high dose 50 mg/ml Ampicillin. Proliferation reduced less than 40%, at same dose with LPS the viability reduced to less than 20%.

The IC₅₀ recorded with second high dose 25mg/ml reduced the growth to 50% while presence of LPS inhibited the growth 5% more at same dose. Interestingly low dose 1% exerted similar inhibition profile to 25 mg/ml of Amp with/out LPS. The results demonstrated the ability of Amp. To interfere with the viability of HCT116 cells this may be via interacting with specific colorectal cancer cell surface receptors, which are usually expressed in cancer cells rather than normal. Those cancer biomarker are play important role in therapy as most anticancer drugs are ligands of most these receptors and could modulate their mode of action to inhibit or stop cancer progression (Hayashi et al., 2013) cells, likewise browsing the possibilities of Ampicillin act as a Ligand (see fig.3.) we have found 14 different human and animal molecular receptor capable of binding

with this drug at various potential degrees which support the objectives of this work.




Fig.1.Three dimension conformer of Ampicillin. Adapted from NCBI, (2016)




Fig.2.Growth inhibition effect of Ampicillin against Colorectal carcinoma. HCT116 cells were incubated with LPS 1 μ g/ml overnight in 96 well plate, then treated with 50, 25, 1 mg/ml Amp for 72 h, then MTT was added to

measure the cellular growth at wave length (540-690)nm. The experiment performed 3 times in triplicate. Error bars represent standard deviation and asterisk refer to significant difference $p < 0.05$ as calculated by TTEST.




Fig.3.Possible Molecular interactions of Ampicillin.

References

- ANAMI, K., OUE, N., NOGUCHI, T., SAKAMOTO, N., SENTANI, K., HAYASHI, T., HINOI, T., OKAJIMA, M., GRAFF, J. M. & YASUI, W. 2010. Search for transmembrane protein in gastric cancer by the Escherichia coli ampicillin secretion trap: expression of DSC2 in gastric cancer with intestinal phenotype. *J Pathol*, 221, 275-84.
- ANAMI, K., OUE, N., NOGUCHI, T., SAKAMOTO, N., SENTANI, K., HAYASHI, T., NAITO, Y., OO, H. Z. & YASUI, W. 2016. TSPAN8, identified by Escherichia coli ampicillin secretion trap, is associated with cell growth and invasion in gastric cancer. *Gastric Cancer*, 19, 370-80.
- FERRONI, P., FORMICA, V., DELLA-MORTE, D., LUCCHETTI, J., SPILA, A., D'ALESSANDRO, R., RIONDINO, S., GUADAGNI, F. & ROSELLI, M. 2016. Prognostic value of glycated hemoglobin in colorectal cancer. *World J Gastroenterol*, 22, 9984-9993.
- GUI, D., ANASTASIO, G., PESCATORI, M. & RONCONI, P. 1990. [Antibiotic prophylaxis with sulbactam/ampicillin in colon surgery]. *Minerva Chir*, 45, 499-502.

- HAYASHI, T., SENTANI, K., OUE, N., OHARA, S., TEISHIMA, J., ANAMI, K., SAKAMOTO, N., MATSUBARA, A. & YASUI, W. 2013. The search for secreted proteins in prostate cancer by the Escherichia coli ampicillin secretion trap: expression of NBL1 is highly restricted to the prostate and is related to cancer progression. *Pathobiology*, 80, 60-9.
- ISE, Y., HAGIWARA, K., SAITOH, S., HONJO, K., SOH, S., KATO, A., KATAYAMA, S., NISHIZAWA, K., HIRANO, M., YOSHIYUKI, T., KIYAMA, T., MITSUHASHI, K., KAMEI, M. & SHIRAGAMI, M. 2004. [Comparison of the effects of prophylactic antibiotic therapy and cost-effectiveness between cefazolin (CEZ) and Sulbactam/Ampicillin (SBT/ABPC) in gastric cancer surgery employing clinical pathway]. *Yakugaku Zasshi*, 124, 815-24.
- KEISER, M. J., ROTH, B. L., ARMBRUSTER, B. N., ERNSBERGER, P., IRWIN, J. J. & SHOICHET, B. K. 2007. Relating protein pharmacology by ligand chemistry. *Nat Biotechnol*, 25, 197-206.
- MENZEL, J., BAUER, J., VON PRITZBAUER, E. & KLEMPA, I. 1996. Perioperative use of ampicillin/sulbactam, cefoxitin and piperacillin/metronidazole in elective colon and rectum surgery: a prospective and randomized quality control study in 422 patients. *Int J Antimicrob Agents*, 6 Suppl, S79-82.
- NASH, A. G. & HUGH, T. B. 1967. Topical ampicillin and wound infection in colon surgery. *Br Med J*, 1, 471-2.
- OO, H. Z., SENTANI, K., MUKAI, S., HATTORI, T., SHINMEI, S., GOTO, K., SAKAMOTO, N., NAITO, Y., ANAMI, K., TRANG, P. T., YANAGIHARA, K., OUE, N. & YASUI, W. 2016. Fukutin, identified by the Escherichia coli ampicillin secretion trap (CAST) method, participates in tumor progression in gastric cancer. *Gastric Cancer*, 19, 443-52.
- OO, H. Z., SENTANI, K., SAKAMOTO, N., ANAMI, K., NAITO, Y., OSHIMA, T., YANAGIHARA, K., OUE, N. & YASUI, W. 2014. Identification of novel transmembrane proteins in scirrhous-type gastric cancer by the Escherichia coli ampicillin secretion trap (CAST) method: TM9SF3 participates in tumor invasion and serves as a prognostic factor. *Pathobiology*, 81, 138-48.
- RAAHAVE, D., HESSELFELDT, P., PEDERSEN, T., ZACHARIASSEN, A., KANN, D. & HANSEN, O. H. 1989. No effect of topical ampicillin prophylaxis in elective operations of the colon or rectum. *Surg Gynecol Obstet*, 168, 112-4.
- TELFORD, J., GENTILE, L., GONDARA, L., MCGAHAN, C. & COLDMAN, A. 2016. Performance of a quantitative fecal immunochemical test in a colorectal cancer screening pilot program: a prospective cohort study. *CMAJ Open*, 4, E668-E673.